Mayo Clinic: Massive dose of measles vax killed cancer

The measles vaccine may be capable of more than just preventing measles. According to the Minneapolis StarTribune, a single, massive dose wiped out blood cancer that had spread inside the body of a patient involved in a clinical trial. While only one of two subjects in the experiment achieved complete remission, the trial provides proof of concept that one large dose of an intravenous viral therapy can eradicate cancer by overwhelming its natural defenses, researcher Dr. Stephen Russell told the paper. More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.